Exo, a Silicon Valley company known for its in-development handheld ultrasound device, announced $40 million in new funding yesterday. GlaxoSmithKline's Investor Action Potential Venture Capital fund was among the Series B+ round's unnamed investors.
Exo said in its announcement that it will be using the funds to wrap up product development for that device, and to bring its data and workflow apps...
